Agios Pharmaceuticals Inc. Stock
Agios Pharmaceuticals Inc. gained 0.850% compared to yesterday.
We see a rather positive sentiment for Agios Pharmaceuticals Inc. with 9 Buy predictions and 1 Sell predictions.
With a target price of 42 € there is a hugely positive potential of 79.49% for Agios Pharmaceuticals Inc. compared to the current price of 23.4 €.
So far the community has only identified positive things for Agios Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | 0.850% | -2.500% | -38.095% | -36.066% | -26.415% | -15.827% | -15.797% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 19.531% | -8.383% | -27.143% | -73.167% | -68.934% |
| Novocure Ltd | -1.160% | 9.135% | 15.722% | -60.508% | -61.023% | -84.133% | -91.990% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -14.490% | -75.357% | -72.809% | -71.362% | -95.447% |
Comments
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) had its price target lowered by analysts at Bank of America Corporation from $54.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Why Shares in Agios Pharmaceuticals Got Crushed Today
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) crashed by 50% by noontime today. The move comes as the market digests a mixed set of topline results from its Phase 3 trial (RISE UP) of its sickle
Agios (AGIO) Q2 Revenue Jumps 45%
Agios Pharmaceuticals (NASDAQ:AGIO), a biotechnology company focused on therapies for rare blood disorders, released its second quarter 2025 earnings on July 31, 2025. The headline was a notable